Ceryvyn Therapeutics Ltd
OPT
Rank in Stocks
#31865
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Share Price
$0.00846342
Last synced: 2026-07-27
Market Cap
$11.27M
Change (1 day)
0.00%
Change (1 year)
-99.75%
Country
AU
Trade Ceryvyn Therapeutics Ltd (OPT)
Category
Healthcare
Revenue for Ceryvyn Therapeutics Ltd (OPT)
Revenue in Jun 2025 TTM: $146.02K
According to Ceryvyn Therapeutics Ltd latest financial reports the company's current revenue (TTM) is $146.02K. In 2024 the company made a revenue of $124.67K a decrease compared to the revenue in the year 2023 that was $161.16K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ceryvyn Therapeutics Ltd from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $146.02K | 478.27% |
| 2025 | $25.25K | -79.75% |
| 2024 | $124.67K | -22.65% |
| 2023 | $161.16K | 28.88% |
| 2022 | $125.05K | 35.95% |
| 2021 | $91.98K | -8.63% |
| 2020 | $100.67K | 27.42% |
| 2019 | $79.01K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | -100.00% |
| 2008 | $13.77K | -15.24% |
| 2007 | $16.24K | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $10.15K | 19.47% |
| 2004 | $8.50K | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 8,645,674.12% |
US
|
|
| $2.23B | 1,525,749.73% |
US
|
|
| $15.74B | 10,782,430.21% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 4,123,589.23% |
NL
|
